Prodrug conversion is a promising approach to cytotoxic gene therapy if an efficient transfer of the generated drug to adjacent cells can be achieved. To maximize the efficacy of this strategy we sought to develop a system that is based on a human enzyme, acts extracellularly yet in close vicinity of the transduced cell and can be used with multiple prodrugs. Results obtained with a secreted version of human ␤-glucuronidase suggested that this enzyme could be a suitable candidate, although a more stringent retention of the
Introduction
The inefficacy of cancer chemotherapy is largely due to dose-limiting, toxic side-effects of conventional drugs and the generation of multidrug-resistant tumor cells due to insufficient drug concentrations at the tumor site. 1 One possibility to circumvent this problem is gene-directed enzyme prodrug therapy (GDEPT), also referred to as molecular chemotherapy. 2, 3 Central to this approach is the tumor-directed delivery of a gene encoding an enzyme that cleaves a systemically applied inactive prodrug to a toxic drug. Since prodrugs usually possess little toxicity, relatively large amounts can be administered, which in turn will lead to high drug concentrations at the tumor. Most GDEPT systems available at present, such as the herpes simplex virus thymidine kinase/ganciclovir system, function intracellularly and thereby limit the efficacy of the system and choice of the prodrug to membrane-permeable molecules. [4] [5] [6] [7] In an attempt to improve this situation, prokaryotic carboxypeptidase G2 displayed on the cell surface has been developed for GDEPT. 8, 9 However, the use of a non-human enzyme may provoke undesired immune responses, particularly if multiple applications are required. We therefore sought to design a GDEPT system that is based on a human enzyme, functions extracellularly and can potentially be used with multiple prodrugs.
␤-Glucuronidase seems to be a particularly suitable candidate as a prodrug-converting enzyme, because the endogenous enzyme is located in lysosomes 10 and therefore not available for conversion of glucuronide pro-enzyme at the site of the producer cell, such as its attachment to the cell surface, would be desirable. Here, we show that the fusion of the transmembrane domain of the human PDGF receptor to a C-terminally truncated form of human ␤-glucuronidase results in its surface accumulation at high steady-state levels. Using a doxorubicin prodrug, we demonstrate that this GDEPT system produces a strong bystander effect and has potent antitumor activity in vivo. Gene Therapy (2001) 8, 1005-1010.
drugs, which are generally hydrophilic and therefore cellimpermeable. In addition, although the pH-optimum of human ␤-glucuronidase is ෂ5, it is also strongly active at pH values typical of the tumor microenvironment (around 6.5).
11 Like other lysosomal enzymes, ␤-glucuronidase contains a signal peptide for protein synthesis at the rough endoplasmic reticulum and N-glycosylation sites for mannose-6-phosphate-dependent sorting in the trans-Golgi network to the lysosomal compartment. 12 We have previously shown that tumor cells transduced to secrete ␤-glucuronidase can efficiently convert a membrane-impermeable doxorubicin prodrug to the toxic drug doxorubicin, and that this GDEPT system can mediate tumor cell killing both in vitro and in vivo. 13 A potential problem with this approach, however, lies in the possibility that the secreted enzyme may leak from the tumor with the result of toxic side-effects and decreased enzyme concentrations at the site of the tumor. In the present study, we report the successful conversion of lysosomal human ␤-glucuronidase to an enzymatically active, cell surface-displayed form, and show its functionality as part of a GDEPT approach in animal models of human carcinomas. We propose that analogous approaches will be applicable to other lysosomal enzymes, which may allow for the establishment of a new class of GDEPT systems based on hydrolytic human enzymes.
Results and discussion
Design of a functional enzyme with a membrane anchor To express the human ␤-glucuronidase on the cell surface for localized extracellular prodrug activation we engineered different forms of the enzyme and tested these for enzymatic activity with the fluorescent substrate 4-methylumbelliferyl-␤-glucuronide (MUG) after transient transfection into COS-7 cells ( Figure 1 and Table 1 ). Based on these assays, a fusion protein of the PDGF receptor transmembrane domain 14 with a ␤-glucuronidase molecule that was C-terminally truncated at Thr-633 (␤633-PDGFR) turned out to be the most promising construct. This C-terminal truncation was essential because of Cterminal processing of the de novo synthesized polypeptide. Deletion of three additional amino acids (␤630-PDGFR) reduced overall activity by Ͼ90% presumably due to elimination of the fourth N-glycosylation site. We also fused the transmembrane domain of the asialoglycoprotein receptor H1 (ASGPR) 15 and the respiratory syncytial virus (RSV) G-protein 16 to N-terminally truncated ␤-glucuronidase lacking the endogenous signal peptide. The ASGPR and RSV G-protein are type II transmembrane proteins with very short intracellular N-terminal domains and very long extracellular C-termini. Its N-terminal portion naturally acts as a combined signal and anchor sequence and directs the orientation of membrane integration. However, proteins with this signal/anchor sequence fused to human ␤-glucuronidase without (RSV-␤G) or with a four-amino acid spacer (RSV-G 4 -␤G) showed very low, if any, enzymatic activity (Table 1) . We therefore performed all further studies with construct ␤633-PDGFR, subsequently referred to as TM-␤Gluc. a Numbers correspond to amino acid positions of the parental wild-type proteins. Position 1 of ␤-glucuronidase corresponds to the Nterminal amino acid of the signal peptide of the unprocessed proform. b Conversion of the ␤-glucuronidase substrate MUG by cell lysates from transiently transfected COS-7 cells. Enzymatic activities (MUG conversion) are indicated relative to ␤-glucuronidase protein levels assessed from the data in Figure 1 . Each + corresponds to a difference in activity of ෂ3-fold. −, no significant activity detectable. c Very low level of expression. PDGFR, platelet-derived growth factor receptor; ASGPR, asialoglycoprotein receptor; RSV-G, respiratory syncytial virus G-protein; G 4 , GlyGly-Gly-Gly spacer; TM, transmembrane.
Cell surface expression of TM-␤Gluc
The subcellular localization of the recombinant TM␤Gluc was analyzed by two different approaches. First, the detergent saponin was used to extract soluble proteins from transiently transfected COS-7 cells after metabolic labeling with 35 S-methionine. 15 Saponin-soluble and insoluble proteins were analyzed by immunoprecipitation with a ␤-glucuronidase-specific monoclonal antibody. For comparison, a secreted ␤-glucuronidase lacking a transmembrane domain was included (s-␤Gluc). 13 As expected, the majority of the s-␤Gluc protein was in the saponin fraction whereas the TM-␤Gluc was found in the fraction of saponin-insoluble proteins (Figure 2 ). Second, cell surface expression of ␤-glucuronidase was analyzed by indirect immunofluorescence of transiently transfected cells and laser scanning microscopy. Unfixed cells were incubated with a ␤-glucuronidase-specific monoclonal antibody and labeled with a Cy3-conjugated secondary antibody. Figure 3 shows a series of confocal microscopy images representing different levels of the same TM-␤Gluc-transfected cell scanned from top to bottom. The data clearly demonstrate expression of TM␤Gluc on the cell surface. In contrast, no fluorescence was detected with cells transfected with control plasmid or s-␤Gluc (data not shown).
Figure 2 Subcellular localization of TM-␤Gluc. Saponin extractability of TM-␤Gluc compared with s-␤Gluc from

Activation of a doxorubicin prodrug by TM-␤Gluc
We next investigated the ability of TM-␤Gluc to cleave the glucuronide prodrug of doxorubicin, ␤-glucuronyldoxorubicin [N-(4-␤-glucuronyl-3-nitrobenzyloxy-carbonyl)-doxorubicin; HMR1826] originally developed for antibody-directed enzyme prodrug therapy 17 and also successfully used for experimental monotherapy.
18 ␤-Glucuronyl-doxorubicin is hydrophilic and cannot pass cell membranes, but after cleavage the generated hydrophobic doxorubicin can enter cells and intercalates into DNA. In the same experiment we sought to assess a potential bystander effect. For this purpose, tumor cells were transiently transfected at a deliberately low transduction efficiency of ෂ2%. Two days after transfection the cells were incubated with prodrug for 16 h. Transfected cells were visualized by indirect immunofluorescence for ␤-glucuronidase (Figure 4 , green fluorescence), while prodrug conversion and spread of the generated drug were assessed by observing the red autofluorescence of intercalated doxorubicin (emission maximum at ෂ600 nm). As shown in Figure 4e , a dramatic bystander effect was seen with the TM-␤Gluc/␤-glucuronyl-doxorubicin system: all cells surrounding the two successfully transduced cells (marked by arrows) were strongly positive for doxorubicin autofluorescence. As expected, untransfected cells showed only weak fluorescence (Figure 4g) , whereas all cells in the s-␤Gluc-transfected culture were equally positive (Figure 4b ) due to the fact that the secreted enzyme can freely diffuse through the culture medium. In contrast, a gradient of decreasing doxorub-
Figure 3 Confocal microscopy of TM-␤Gluc-transduced cells. COS-7 cells were transiently transfected with TM-␤Gluc using DEAE-dextran and analyzed by indirect immunofluorescence 48 h later. The images show different levels of the same cell scanned from top (A) to bottom (F).
Gene Therapy icin autofluorescence was seen around TM-␤Gluc-transduced cells confirming that the enzyme is not released from the cells. This observation also indicates that the observed bystander effect is mediated by the generated doxorubicin.
In vivo functionality of the TM-␤Gluc-based GDEPT system Finally, we investigated the efficacy of the TM-␤Gluc/␤-glucuronyl-doxorubicin system in vivo using two different human tumor models, JEG-3 choriocarcinoma and A549 lung adenocarcinoma, stably transduced with TM␤Gluc. These cells, in a mixture with ෂ50% non-expressing cells, were injected s.c. into nu/nu mice. Expression of TM-␤Gluc in a similar fraction of cells in the established tumors was confirmed by histochemistry (data not shown). For comparison, tumors were also established from non-expressing control cells. At a tumor size of ෂ40 mm 3 prodrug was injected into the tail vein and tumor growth was monitored. As shown in Figures 5 and 6 , the in vivo growth behavior of TM-␤Gluc-transduced JEG-3 and A549 cells in the absence of prodrug treatment resembled that of the non-transduced parental cells, and prodrug treatment had no significant effect on the nontransduced tumor cells. In contrast, tumors established from TM-␤Gluc expressing JEG-3 cells regressed after a single prodrug application ( Figure 5 ) and some of these reappeared only after Ͼ20 days. Two of six mice were still tumor-free after Ͼ6 months. Likewise, a single prodrug treatment strongly inhibited the growth of TM␤Gluc expressing A549 tumors for more than 50 days ( Figure 6 ). The stronger therapeutic effect seen with JEG-3 tumors is presumably due to the fact that JEG-3 cells are more sensitive to doxorubicin than A549 cells (IC 50 in vitro ෂ30 nm for JEG-3 versus ෂ100 nm for A549 cells). These results clearly demonstrate the functionality of the TM-␤Gluc/␤-glucuronyl-doxorubicin system established in the present study.
In summary, we have constructed a cell surfacedisplayed form of the normally lysosomal human ␤-glucuronidase, which is able to convert an inactive glucuronidated prodrug to the cytotoxic doxorubicin with high efficiency. We have demonstrated that the generated drug is efficiently taken up by non-transduced cells resulting in a pronounced bystander effect. Using human xenograft models, we have also shown that TM-␤Gluc in combination with the prodrug efficiently induces tumor cell killing in vivo, even after a single prodrug application. This GDEPT system is characterized by multiple features that collectively might represent a substantial advantage when compared with the systems currently in use. (1) ␤-Glucuronidase is a human enzyme that is nonimmunogenic. ( 2) The TM-␤Gluc system functions extracellularly, thereby allowing for an extended bystander effect. (3) The TM-␤Gluc is attached to the transduced cell which should minimize leakage from the site of the tumor. With the currently available tools, ie stably transfected tumor cell lines, this hypothesis is, however, difficult to test. Due to the different localization of the enzyme the system can hardly be standardized, since this would require the formidable task of identifying cell lines giving rise to similar levels of secreted and membranedisplayed enzyme, respectively. A comparative analysis can be conclusively addressed once systemically applicable, targeted vectors delivering different forms of ␤-glucuronidase to a tumor are available, since this will obviate the need for any standardization other than the application of similar amounts of vector particles. We have initiated studies towards this goal. (4) The ␤-glucuronyl-doxorubicin prodrug shows little toxicity when delivered systemically, 19, 20 so that high drug concentrations are achievable locally at the tumor. (5) ␤-Glucu-ronyl-doxorubicin is hydrophilic which prevents its entry into, and thus its activation of non-transduced cells. (6) The generated drug doxorubicin is lipophilic and therefore rapidly taken up by cells in the vicinity of the transduced cell, thus limiting its escape into the circulation, which is an important consideration in view of its strong cardiotoxicity. (7) Extracellular ␤-glucuronidase is found at high levels in necrotic tumor areas 18, 21 which will potentiate the efficacy of TM-␤Gluc-based GDEPT approaches. (8) Other ␤-glucuronide products have been described, 19, [22] [23] [24] [25] [26] [27] [28] [29] suggesting that the same enzyme can potentially be used with a plethora of other chemotherapeutics. This also opens up the possibility of combining different prodrugs similar to conventional chemotherapy. (9) Finally, analogous approaches should also be applicable to other hydrolytic lysosomal enzymes thus providing an opportunity for expanding the very small group of human enzymes 30 currently available for GDEPT approaches.
Cells expressing either s-␤Gluc (a-c) or TM-␤Gluc (d-f) or non-transduced control JEG-3 cells (g and h) were incubated with ␤-glucuronyl-doxorubicin for 16 h. (a, d) detection of ␤-glucuronidase by indirect immunofluorescence (green); (b, e, g) red autofluorescence of nuclear doxorubicin (cleaved prodrug); (c, f, h) staining with Hoechst 33258 to visualize nuclei (blue).
Materials and methods
Plasmid constructs
Human ␤-glucuronidase c-DNA cloned into the pcDNA3 expression vector was used to derive all other constructs by standard cloning procedures. 13 All heterologous sequences were inserted using synthetic oligonucleotides and plasmids were verified by DNA sequencing. The precise amino acid sequences and points of insertion into ␤-glucuronidase are shown in Table 1 . All plasmids were amplified in E. coli and purified according to a standard protocol (Qiagen, Hilden, Germany). For generating stable clones TM-␤Gluc was cloned into the LNCX vector (Clontech, Palo Alto, CA, USA). In all constructs the inserted gene is driven by the CMV promoter.
Cell culture
The human choriocarcinoma cell line JEG-3 (obtained from A Wellstein, Georgetown University, Washington DC), the human lung adenocarcinoma cell line A549 (kindly provided by K Havemann, Marburg, Germany), and COS-7 cells (ATCC) were cultured and passaged as described previously. 13 Stable JEG-3 and A549 clones were isolated after infection with an amphotropic retrovirus generated by transfection of Phoenix A cells according to the manufacturers protocol (Clontech).
Determination of enzymatic activity and protein expression COS-7 cells grown on 3-cm dishes were transiently transfected with the different ␤-glucuronidase constructs (Table 1 ) using the DEAE-dextran method. 25 Two days later cells were lysed with 250 l 0.5% sodium-deoxycholate in PBS. Aliquots were used for determination of enzymatic activity and immunoblotting. A solid phase enzyme-linked assay was used for quantification of enzymatic activity. Microtiter plates were coated with a monoclonal antibody against native human ␤-glucuronidase (hybridoma supernatant 2118/157, obtained from HH Sedlacek, Aventis Pharma, Marburg, Germany), blocked with 2% skim milk, and incubated with 50 l cell extracts. Afterwards, samples were processed as described. 17 For immunoblot analysis, aliquots of cell extracts were separated by SDS-polyacrylamide gel electrophoresis (10%).
Gene Therapy
The proteins were transferred on to nitrocellulose by electrophoresis using a semi-dry blotting chamber. The membrane was blocked with 5% skim milk for 2 h and incubated with the primary antibody (hybridoma supernatant 2156/94, obtained from HMR, Marburg, Germany, diluted 1/10) for 2 h at room temperature. Unbound antibody was washed five times with PBS. The membrane was then incubated with the secondary antibody (peroxidase conjugate; Santa Cruz, Heidelberg, Germany) for 2 h at RT, washed, and the enzyme expression was detected upon addition of ECL (Amersham Pharmacia Biotech, Freiburg, Germany).
Saponin extraction and immunoprecipitation COS-7 cells were transfected by the DEAE-dextran technique on 6-cm dishes. 31 Forty-eight hours later, the cells were labeled for 3 h with 0.2 mCi/ml 35 S-methionin (Amersham Pharmacia Biotech) in DMEM + 10% dialyzed FBS. The cell monolayer was washed with PBS and treated with a buffer containing 0.1% saponin for 10 min. 15 The supernatant containing the saponin-soluble proteins was collected, and the remaining insoluble material was scraped from the dish in RIPA buffer (10 mm Tris pH 7.5, 150 mm NaCl, 0.25% SDS, 1% sodium deoxycholate, 1% Nonidet P40, 1 mm DTT, protease inhibitors: 0.5 mm PMSF, 50 g/ml Aprotinin, 50 g/ml Leupeptin). Both fractions were analyzed by immunoprecipitation using hybridoma supernatant 2118/157 (obtained from HMR) as described. 13 Immunostaining and confocal microscopy COS-7 cells were transiently transfected with DEAEdextran. Forty-eight hours later, indirect immunostaining was performed using the monoclonal antibody against human ␤-glucuronidase (hybridoma supernatant 2118/157) and a DTAF-labeled secondary anti-mouse antibody (Dianova, Hamburg, Germany). Cells were postfixed with 3.7% formaldehyde and observed under a confocal microscope.
Detection of prodrug conversion
Two days after transfection cells were incubated for 16 h with 15 m of the ␤-glucuronyl-doxorubicin prodrug HMR1826 (obtained from HH Sedlacek). Afterwards, the cells were fixed with 3.7% formaldehyde. Converted prodrug was detected as red doxorubicin autofluorescence. Transfected cells were detected by indirect immunofluorescence as described above. Cell nuclei were visualized by staining with Hoechst 33258.
In vivo studies Nude mice (strain CD-1 nu/nu; three to six animals per group) were injected s.c. with 10 6 control or TM-␤Gluc cells (in 200 l PBS) using a 21 G needle. After 1-2 weeks tumors were visible. At a size of ෂ40 mm 3 , prodrug (100-250 mg/kg) was injected i.v., and tumor growth was measured at regular intervals.
